|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 555 11th STREET, NW |
Address2 | Suite #300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anita Drummond |
Date | 9/17/2020 2:53:08 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act; and issues relating to veterans cancer screenings with respect to the Military Construction and Veterans Affairs Appropriations Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Natl Institutes of Health (NIH), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Phelan |
|
|
|
Gregg |
Haifley |
|
|
|
Richard |
Woodruff |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Maggie |
Osborne |
|
|
|
Greta |
Johnson |
|
|
|
Katrina |
Kamm |
|
|
|
Lauren |
Coatoam |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Paul |
Holmes |
|
|
|
Lynda |
Barbour |
|
|
|
Mary |
Kemp |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller, Johnson repeal. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Phelan |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Gregg |
Haifley |
|
|
|
Richard |
Woodruff |
|
|
|
Katrina |
Kamm |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Rachel |
Marcus |
|
|
|
Emily |
White |
|
|
|
Lynda |
Barbour |
|
|
|
Christopher |
Feeney |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations, and H.R. 2194 Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), White House Office, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Woodruff |
|
|
|
Gregg |
Haifley |
|
|
|
Katrina |
Kamm |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Matthew |
Phelan |
|
|
|
Greta |
Johnson |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Rachel |
Marcus |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
HR1 tax bill, issues relating to the tax treatment of nonprofits, including charitable deductions, elimination of the individual fee for the Affordable Care Act, deduction of health care costs by individual tax payers, and availability of the Orphan Drug Tax Credit. Also expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988 and S. 2123. Also, creating parity in taxation of tobacco products respecting S. 1837
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Woodruff |
|
|
|
Gregg |
Haifley |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Rachel |
Marcus |
|
|
|
Keysha |
Brooks-Coley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Preservation of the Prevention and Public Health Fund and reauthorization of the CHIP program and FQHCs respecting H.R. 3922. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. Issues regarding access to care respecting the Bi-partisan Health Care Stabilization Act (Alexander-Murray) and S 1835, The Lower Premiums through Reinsurance Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), White House Office, Food & Drug Administration (FDA), State - Dept of (DOS), Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Keysha |
Brooks-Coley |
|
|
|
Matthew |
Phelan |
|
|
|
Richard |
Woodruff |
|
|
|
Gregg |
Haifley |
|
|
|
Maggie |
Osborne |
|
|
|
Greta |
Johnson |
|
|
|
Katrina |
Kamm |
|
|
|
Lauren |
Coatoam |
|
|
|
Caroline |
Powers |
|
|
|
Rosalie |
Abbott |
|
|
|
Sherry |
McCammon |
|
|
|
Rachel |
Marcus |
|
|
|
Emily |
White |
|
|
|
Paul |
Holmes |
|
|
|
Mary |
Kemp |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |